Jazz Pharmaceuticals plc
JAZZ
$181.37
-$0.65-0.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.38% | 7.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.38% | 7.69% | |||
| Cost of Revenue | -12.38% | 10.85% | |||
| Gross Profit | 8.80% | 7.29% | |||
| SG&A Expenses | 15.49% | 5.79% | |||
| Depreciation & Amortization | 0.82% | 3.86% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.22% | 5.79% | |||
| Operating Income | 17.35% | 14.86% | |||
| Income Before Tax | 2,218.80% | 101.22% | |||
| Income Tax Expenses | 102.05% | -1,311.90% | |||
| Earnings from Continuing Operations | -19.08% | 134.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.08% | 134.99% | |||
| EBIT | 17.35% | 14.86% | |||
| EBITDA | 10.37% | 9.36% | |||
| EPS Basic | -19.56% | 135.28% | |||
| Normalized Basic EPS | 21.95% | 20.58% | |||
| EPS Diluted | -21.39% | 134.75% | |||
| Normalized Diluted EPS | 19.15% | 18.80% | |||
| Average Basic Shares Outstanding | 0.60% | -0.81% | |||
| Average Diluted Shares Outstanding | 2.97% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||